Unknown

Dataset Information

0

Dystrophin Cardiomyopathies: Clinical Management, Molecular Pathogenesis and Evolution towards Precision Medicine.


ABSTRACT: Duchenne's muscular dystrophy is an X-linked neuromuscular disease that manifests as muscle atrophy and cardiomyopathy in young boys. However, a considerable percentage of carrier females are often diagnosed with cardiomyopathy at an advanced stage. Existing therapy is not disease-specific and has limited effect, thus many patients and symptomatic carrier females prematurely die due to heart failure. Early detection is one of the major challenges that muscular dystrophy patients, carrier females, family members and, research and medical teams face in the complex course of dystrophic cardiomyopathy management. Despite the widespread adoption of advanced imaging modalities such as cardiac magnetic resonance, there is much scope for refining the diagnosis and treatment of dystrophic cardiomyopathy. This comprehensive review will focus on the pertinent clinical aspects of cardiac disease in muscular dystrophy while also providing a detailed consideration of the known and developing concepts in the pathophysiology of muscular dystrophy and forthcoming therapeutic options.

SUBMITTER: D'Amario D 

PROVIDER: S-EPMC6162458 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dystrophin Cardiomyopathies: Clinical Management, Molecular Pathogenesis and Evolution towards Precision Medicine.

D'Amario Domenico D   Gowran Aoife A   Canonico Francesco F   Castiglioni Elisa E   Rovina Davide D   Santoro Rosaria R   Spinelli Pietro P   Adorisio Rachele R   Amodeo Antonio A   Perrucci Gianluca Lorenzo GL   Borovac Josip A JA   Pompilio Giulio G   Crea Filippo F  

Journal of clinical medicine 20180919 9


Duchenne's muscular dystrophy is an X-linked neuromuscular disease that manifests as muscle atrophy and cardiomyopathy in young boys. However, a considerable percentage of carrier females are often diagnosed with cardiomyopathy at an advanced stage. Existing therapy is not disease-specific and has limited effect, thus many patients and symptomatic carrier females prematurely die due to heart failure. Early detection is one of the major challenges that muscular dystrophy patients, carrier females  ...[more]

Similar Datasets

| S-EPMC4456621 | biostudies-other
| S-EPMC10219232 | biostudies-literature
| S-EPMC7852459 | biostudies-literature
| S-EPMC7607071 | biostudies-literature
2019-03-15 | GSE125216 | GEO
| S-EPMC7554875 | biostudies-literature
2019-02-27 | GSE127208 | GEO
| S-EPMC6558499 | biostudies-literature
| S-EPMC10492755 | biostudies-literature
| S-EPMC8199244 | biostudies-literature